Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$7.31 – $8.16
100% from low
Exchange
OTC Link
ADRC
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.23B | $1.30B | $1.36B | $1.59B | $1.45B | $1.46B | $1.60B | $1.86B |
| Cost of revenue | $372.4M | $407.9M | $422.4M | $430.4M | $446.6M | $1.32B | $1.42B | $1.70B |
| Gross profit | $860.5M | $896.0M | $937.7M | $182.6M | $999.5M | $148.8M | $171.8M | $161.1M |
| Gross margin | 69.8% | 68.7% | 68.9% | 11.5% | 69.1% | 10.2% | 10.8% | 8.7% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $64.9M | $56.8M | $10.6M | $30.5M | $36.1M | $40.4M | $48.1M | $4.2M |
| EBITDA | $125.9M | $125.7M | $73.7M | $100.4M | $97.6M | $117.0M | $122.2M | $66.7M |
| Net income | $49.0M | $43.3M | $1.5M | $28.3M | $25.1M | $38.7M | $43.4M | $33.1M |
| Net margin | 4.0% | 3.3% | 0.1% | 1.8% | 1.7% | 2.6% | 2.7% | 1.8% |
| EPS (diluted) | 0.37 | 0.33 | 0.01 | 0.21 | 0.19 | 0.29 | 0.34 | 0.25 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.8B | $0.00 | $0.00–$0.00 | 0 |
| 2027 | $1.9B | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
RHOEN KLINIKUM UNSP/ADR
No one on the platform currently holds RKAGY.
No tracked institution reports a position in RKAGY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-29 | $0.1162 | 2026-06-22 |
| 2025-06-05 | $0.0570 | 2025-06-23 |
No one on the platform has traded RKAGY yet.
| +0.00% |
| $1.2B |
| — |
| LTGHYLife Healthcare Group Holdings Limited | $2.49 | +0.81% | $891M | — |
| NWKHYNetcare Limited | $7.17 | +0.00% | $844M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 26.3× earnings vs its 26.9× historical median P/E.
Fair value ≈ $8.34 · price $8.16 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.